Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,609.00
Bid: 1,608.50
Ask: 1,609.50
Change: 9.00 (0.56%)
Spread: 1.00 (0.062%)
Open: 1,608.00
High: 1,616.00
Low: 1,604.50
Prev. Close: 1,600.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-Santarus, Sequenom, Durect, Tremor, Gap

Fri, 08th Nov 2013 12:44

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Nov 8 (Reuters) - U.S. stock index futures advanced onFriday, indicating the S&P 500 will rebound from its biggestdaily decline since late August, ahead of a key report on thelabor market. S&P 500 futures was up 3.6 points, DowJones industrial average futures was up 11 points andNasdaq 100 futures was up 12 points.

** TWITTER INC, Thursday close $44.90, up 0.8 pctpremarket

The micro-blogging site's shares jumped 73 percent in afrenzied trading debut that drove the seven-year-old company'smarket value to around $25 billion and evoked the heady days ofthe dot-com bubble.

** SANTARUS INC, Thursday close $, up 37 pct aftermarket

** SALIX PHARMACEUTICALS LTD, Thursday close$71.31, up 9.3 pct after market

Salix said it will buy Santarus for about $2.6 billion,gaining two new gastroenterology drugs to strengthen its leadingpresence in that market.

** SEQUENOM INC, Thursday close $1.70, up 23 pctafter market

The genetic testing company reported a smaller-than-expectedthird-quarter loss on Thursday due to higher sales of itsprenatal test designed to detect fetal chromosomalabnormalities.

** DURECT CORP, Thursday close $1.54, down 20percent after market

The drugmaker said it is offering shares in an underwrittenpublic offering. The company had about 102 million sharesoutstanding as of Thursday.

** INSULET CORP, Thursday close $37.05, down 8 pctafter market

The medical device maker reported a muchbigger-than-expected third-quarter loss on Thursday as operatingexpenses rose due to the settlement of a patent lawsuit withMedtronic Inc and the launch of a version of its insulinmanagement system OmniPod.

** PRICELINE.COM INC, Thursday close $1022.89, up1.6 pct premarket

The online travel agency known for its name-your-own priceauction, posted a higher-than-expected quarterly profit onThursday as bookings increased.

** TREMOR VIDEO INC, Thursday close $9.26, down 30pct after market

The online video advertising provider reportedlower-than-expected third-quarter results on Thursday and cutits revenue forecast for 2013. Canaccord Genuitycuts its rating on the stock to "hold" from "buy" and its pricetarget by $3.50 to $9.

* CHEMOCENTRYX INC, Thursday close $4.67, up 7 pctpremarket

The company reported a smaller-than-expected quarterly lossdue to lower expenses and higher revenue from its partnerGlaxoSmithKline Plc, which is funding Chemocentryx drugto treat a disease that causes inflammation of blood vessels inthe kidney.

** WALT DISNEY CO, Thursday close $67.15

The company reported a 12 percent gain in profit that beatWall Street expectations, lifted by higher visitor spending atU.S. theme parks, increased consumer product sales and itssummer animated movie hit "Monsters University." Shares ofDisney, which have gained nearly 35 percent this year, slipped1.8 percent in after-hours trading to $65.94.

** MOLYCORP INC, Thursday close $4.76

The rare earths producer has seen demand and prices for itsproducts rise from their second-quarter lows, the company'schief executive said on Thursday, although the company reporteda wider third-quarter loss.

** BLACKBERRY LTD , Thursday close $6.5

The company will pay its new interim CEO a base salary of $1million, a bonus of up to twice that amount as well as stockawards potentially worth some $85 million, in the hopes ofturning around Canada's most prominent technology company.

** COCA-COLA CO, Thursday close $40.05

The company said it will invest over $4 billion in China andbuild new plants between 2015 and 2017, to counter competitionwhich is chipping away at its share of the country's 421 billionyuan ($69.12 billion) soft drinks market.

** PIXELWORKS INC, Thursday close $4.39, down 8.8pct after market

The digital display chip maker's third-quarter results camein below analysts' expectations on Thursday due to lower chiprevenue.

** GROUPON INC,Thursday close $9.50, up 1.3 pctpremarket

The daily coupon website reported a third-quarter profitthat beat analysts' estimates as strong growth in North Americahelped offset a decline in international revenue.

** SPROUTS FARMERS MARKET INC, Thursday close$46.58, down 4.8 pct after market

The retailer of natural and organic foods on Thursday saidaffiliates of Apollo Global Management LLC, and certain otherstockholders, will sell up to 22.5 million shares in a secondaryoffering.

** AMARIN CORP, Thursday close $1.41, up 6.3 pctafter market

The drugmaker reported a smaller-than-expected third-quarterloss on Thursday as sales of its fish-oil drug Vascepa, whichlowers a type of blood fat, jumped 52 percent from the secondquarter. Total prescriptions for Vascepa were up 58 percent fromthe preceding quarter, Amarin said in a statement.

** FIREEYE INC, Thursday close $38.03, up 9 pctafter market

The technology firm that helps companies fend off cyberattacks, gave a revenue outlook for 2014 that came in ahead ofWall Street forecasts as it posted results for the first timesince it went public in September in one of this year's hottestIPOs.

** GAP INC, Thursday close $37.75, up 8 pct aftermarket

The apparel chain's October same-store sales rose 4 percent,well ahead of the analysts' average estimate of 0.1 percent.

** ARENA PHARMACEUTICALS INC, Thursday close $4.08,up 5 pct after market

The company said Japanese drugmaker Eisai Co Ltd will market its diet drug in most markets worldwide as part ofan expanded agreement, under which the companies will alsodevelop the drug for other indications.

** TALISMAN ENERGY INC Thursday close $11.71

The company said it would sell a stake in some ofits natural gas assets in British Columbia's Montney field toMalaysia-controlled Progress Energy Canada Ltd for C$1.5 billion($1.44 billion) as it restructures global operations.

** JOHNSON & JOHNSON, Thursday close $92.69

Healthcare conglomerate Danaher Corp DHR.N has teamed upwith Blackstone Group LP BX.N to bid for the company'sdiagnostics unit, which makes blood screening equipment andlaboratory blood tests and could fetch more than $4 billion,according to people familiar with the matter.

** NVIDIA CORP, Thursday close $14.54, up 2 pctafter market

The graphics chipmaker gave a revenue forecast for thecurrent quarter that was shy of Wall Street's expectations asthe company faces tough competition in tablets and a slowpersonal computer market.

** GENCO SHIPPING AND TRADING LTD, Thursday close$2.66, down 2.2 pct after market

Analysts at Wells Fargo Securities said the dry bulkshipper, which has short-term debt of $1.5 billion, was likelyto breach its debt agreements. "It remains increasingly unlikelythat Genco Shipping will be able to maintain covenant compliancethrough March 31, 2014," analyst Michael Webber said.

** COSTA INC, Thursday close $19.98

Essilor International said it would buy Costa, amaker of premium sport sunglasses, in a $270 million deal thatwould help the French company tap into the growing prescriptionsun lens market.

(Compiled by Natalie Grover; Editing by Don Sebastian)

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.